EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Zebrafish Xenograft Model for Predicting Cisplatin Efficacy in Muscle‐Invasive Bladder Cancer

Yusuke Sugino iD, Xin Bao, Sho Sekito, Shiori Miyachi, Takumi Kageyama iD, Takeshi Sasaki, Kouhei Nishikawa, Toshio Tanaka, Manabu Kato, Yasuhito Shimada, Keishi Takano, Raku Son und 5 weitere

Cancer Science · 2025

DOI: 10.1111/cas.70217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Yusuke Sugino und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Japan. Hauptthemen laut MEDLINE: Cisplatin, Urinary Bladder Neoplasms, Xenograft Model Antitumor Assays, Antineoplastic Agents. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takeda Science Foundation, YOKOYAMA Foundation for Clinical Pharmacology, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The standard treatment for muscle‐invasive bladder cancer (MIBC) is cisplatin (CDDP)‐based neoadjuvant chemotherapy (NAC) followed by radical cystectomy. However, only about 40% of patients respond to NAC, and tools to predict individual responses remain limited. The zebrafish patient‐derived xenograft (zPDX) model offers a rapid and cost‐effective platform for functional drug testing, but its application to MIBC has not yet been established. In this study, we developed a zPDX model optimized for evaluating CDDP sensitivity using clinical bladder cancer specimens. This model was validated through three steps: (1) evaluation of CDDP response in zPDXs derived from cell lines, (2) comparison of drug responses between mouse PDX (mPDX) and zPDX models, and (3) correlation of zPDX responses with clinical outcomes. The robustness of step 1 was demonstrated through complementary assays, including temperature optimization, in vivo platinum quantification, fluorescent dye validation, Cap Analysis of Gene Expression (CAGE), and whole‐mount immunofluorescence. An image‐based platform for quantifying drug response by measuring fluorescent area was established and applied in steps 2 and 3. Step 2, using mPDXs, provided essential technical validation before applying the protocol to clinical samples. In step 3, patient‐derived tumors were transplanted into zebrafish, allowing successful prediction of CDDP efficacy. Despite the small patient cohort, this study provides fundamental evidence supporting zPDX as a clinically relevant and experimentally validated tool for functional assessment of CDDP sensitivity in bladder cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinUrinary Bladder NeoplasmsXenograft Model Antitumor AssaysAntineoplastic AgentsAnimalsZebrafishHumansMiceCell Line, TumorDisease Models, AnimalNeoadjuvant TherapyFemaleNeoplasm Invasiveness

Stichwörter der Autor:innen

PDXbladder cancercisplatinxenograftzebrafish

Substanzen

CisplatinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Japan.
  • Center for Medical Zebrafish Research, Mie University, Tsu, Japan.
  • Institute for the Advanced Study of Human Biology, Kyoto University, Kyoto, Japan.
  • Department of Systems Pharmacology, Mie University Graduate School of Medicine, Tsu, Japan.
  • Department of Urology, Aichi Cancer Center, Nagoya, Japan.
  • Department of Integrative Pharmacology, Mie University Graduate School of Medicine, Tsu, Japan.

ORCID-Profile: Yusuke Sugino, Takumi Kageyama, Takahiro Inoue

Förderung

  • Takeda Science Foundation
  • YOKOYAMA Foundation for Clinical Pharmacology
  • Japan Society for the Promotion of Science
  • The Japanese Urological Association Young Researcher Promotion
  • the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT)
  • Ministry of Education, Culture, Sports, Science and Technology

Zitieren

APA

Sugino, Y., Bao, X., Sekito, S., Miyachi, S., Kageyama, T., Sasaki, T., Nishikawa, K., Tanaka, T., Kato, M., Shimada, Y., Takano, K., Son, R., Zang, L., Nakayama, K., Watanabe, M., Murakawa, Y., & Inoue, T. (2025). Zebrafish Xenograft Model for Predicting Cisplatin Efficacy in Muscle‐Invasive Bladder Cancer. Cancer Science. https://doi.org/10.1111/cas.70217

Vancouver

Sugino Y, Bao X, Sekito S, Miyachi S, Kageyama T, Sasaki T, et al. Zebrafish Xenograft Model for Predicting Cisplatin Efficacy in Muscle‐Invasive Bladder Cancer. Cancer Science. 2025. doi:10.1111/cas.70217

BibTeX
@article{Sugino2025,
  author = {Sugino, Yusuke and Bao, Xin and Sekito, Sho and Miyachi, Shiori and Kageyama, Takumi and Sasaki, Takeshi and Nishikawa, Kouhei and Tanaka, Toshio and Kato, Manabu and Shimada, Yasuhito and Takano, Keishi and Son, Raku and Zang, Liqing and Nakayama, Kenji and Watanabe, Masatoshi and Murakawa, Yasuhiro and Inoue, Takahiro},
  title = {Zebrafish Xenograft Model for Predicting Cisplatin Efficacy in Muscle‐Invasive Bladder Cancer},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.70217}
}
Kostenlos starten →